Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
08 oct. 2021 17h23 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes...
Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
10 sept. 2021 08h29 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual...
FDA Completes On-site Pre-Approval Inspection of Liquidia’s Morrisville, North Carolina Facility
18 août 2021 16h15 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval...
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent
12 août 2021 08h00 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR)...
Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update
10 août 2021 07h00 HE
|
Liquidia Corporation
Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunityResubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powderImproved balance sheet with...
Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021
03 août 2021 07h00 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021....
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
02 juin 2021 07h00 HE
|
Liquidia Corporation
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)...
Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference
26 mai 2021 07h00 HE
|
Liquidia Corporation
MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and...
Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration
24 mai 2021 16h05 HE
|
Liquidia Corporation
MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of...
Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update
13 mai 2021 07h00 HE
|
Liquidia Corporation
- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery- Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder- Improved financial position...